Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Fort Lauderdale, FL, US. The stock last traded at $1.96, down 0.51% on the session, giving a market capitalisation of $4.8M. On trailing twelve-month figures it carries a trailing P/E of -0.90, a net margin of -136966.7%. Its beta of -1.00 implies it has historically moved less than the broad market.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Alaunos Therapeutics, Inc. is most often compared with the following Healthcare names: